Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial

Authors:

Abstract
No abstract available
Funding Information
  • Mitsubishi Tanabe Pharma Corporation
  • Boehringer Ingelheim
  • Daiichi Sankyo Company
  • National Institute of Neurological Disorders and Stroke
  • Otsuka Pharmaceutical
  • Dainippon Sumitomo Pharma
  • Shionogi
  • AstraZeneca
  • National Institutes of Health
  • Takeda Pharmaceutical Company
  • Bayer
  • Otsuka Pharmaceutical
  • Sanofi
  • Bristol-Myers Squibb

This publication has 31 references indexed in Scilit: